Mometasone furoate prescribing across the NHS.
This line is 97% nasal spray: mometasone is England's hay fever and rhinitis steroid, 3m items a year for £14m, peaking reliably every early summer. Generic pricing has made it the default steroid spray, and the seasonality in its chart is among the cleanest on the site.
The NHS in England dispensed 2,937,237 prescription items of Mometasone furoate in the 12 months to May 2026, across primary care and hospitals.
Spending on Mometasone furoate over those 12 months was £12.9m at net ingredient cost, the list price of what was dispensed before any discounts.
Items were down 0.6% on the previous 12 months.
100% of Mometasone furoate volume moved through primary care and 0% through hospital pharmacies.
Mometasone furoate is the largest of 9 chemical substances in Drugs used in nasal allergy (BNF 12.2.1), by items dispensed.
Among Integrated Care Boards, NHS Cheshire and Merseyside ICB dispensed the highest volume of Mometasone furoate.
Source: NHS Business Services Authority open data (English Prescribing Data and SCMD), OGL v3.0. Items count prescriptions dispensed, not patients treated.
| Month | Items | Spend (NIC) |
|---|---|---|
| May 2026 | 250,837 | £780k |
| April 2026 | 262,528 | £819k |
| March 2026 | 265,747 | £974k |
| February 2026 | 232,427 | £856k |
| January 2026 | 252,395 | £926k |
| December 2025 | 246,578 | £1.1m |
| November 2025 | 224,088 | £1.0m |
| October 2025 | 244,613 | £1.1m |
| September 2025 | 232,812 | £1.2m |
| August 2025 | 217,295 | £1.1m |
| July 2025 | 248,035 | £1.3m |
| June 2025 | 259,882 | £1.8m |
The same series as the chart, most recent month first. The full monthly history, as CSV, sits behind Apply.
36.5% of its class.
Mometasone furoate is the largest of 9 chemical substances in Drugs used in nasal allergy (BNF 12.2.1), by items dispensed in May 2026. The full class league, who's gaining, and the month-by-month share movement sit behind Apply.
Average items by calendar month across the full history, indexed to the annual mean.
Mometasone furoate across all 36 ICBs.
Every Integrated Care Board in England, shaded by how much mometasone furoate its GPs dispense per head of population. Hover an ICB to name it. The ranked figures for all 36 ICBs, and the drill-down to practice level, are in the full report.
Darker shading marks where Mometasone furoate is dispensed most per head of population. Exact figures for every ICB, and the drill-down to practice level, are in the full report.
Zoomed out to the 7 NHS regions.
The same 12 months rolled up to NHS England's seven regions, ranked by intensity.
The teaser view.
Three rows each. The full 36-ICB view, every prescribing organisation, every strength and the hospital picture sit below the fold, behind Apply.
- 1 NHS Cheshire and Merseyside ICB 181k
- 2 NHS North East and North Cumbria ICB 178k
- 3 NHS West and North London ICB 170k
- – + 33 more. Unlock the full 36-ICB table. Unlock →
- 1 NHS Derby and Derbyshire ICB +4.6%
- 2 NHS North East and North Cumbria ICB +2.6%
- 3 NHS Central East ICB +2.1%
- – + 33 more. Unlock every ICB, ranked. Unlock →
- 1 Mometasone 50micrograms/dose nasal spray 98%
- 2 Nasonex 50micrograms/dose nasal spray 3%
- 3 Clarinaze Allergy Control 0.05% nasal spray 0%
- – + 0 more. Unlock every strength and pack. Unlock →
Split of items across NHSBSA primary care and SCMD hospital dispensing.
Prescribing by deprivation.
Items per 1,000 registered patients by deprivation decile (1 = most deprived), practice deprivation weighted by where each practice's patients live. Read the shape rather than the absolute level: the most and least deprived deciles cover far fewer practices, and age structure drives much of the gradient.
The devolved nations.
| Nation | Items · 12 months | Data to |
|---|---|---|
| England | 2.9m | May 2026 |
| Northern Ireland | 73k | May 2026 |
| Scotland | 347k | April 2026 |
| Wales | 188k | April 2026 |
Each nation publishes its own community prescribing data, with different coding and list rules, so read these per-nation rather than as an exact UK total. Sources: NHSBSA (England), Public Health Scotland.
What open data won't tell you about mometasone furoate.
Skin preparations of the same molecule sit under a different chemical code, so this page is the nose's market alone, and OTC steroid sprays compete with every item of it.
Asked and answered.
Is mometasone furoate prescribing rising or falling in the NHS?
Falling. England dispensed 2,937,237 items of Mometasone furoate in the 12 months to May 2026, down 0.6% on the previous 12 months. Items count prescriptions dispensed, not patients treated, so the change can reflect dose and duration shifts as well as patient numbers.
How much does the NHS spend on mometasone furoate?
£12.9m at net ingredient cost in the 12 months to May 2026. Net ingredient cost is the list price of the medicine before discounts and rebates; the NHS's final bill, especially for hospital medicines, is usually lower.
Where in England is mometasone furoate prescribed most?
By raw volume, NHS Cheshire and Merseyside ICB dispensed the most mometasone furoate in the last 12 months. Raw volume favours the biggest populations; the map on this page shades every ICB by items per head to correct for that.
How up to date is this data?
This page runs to May 2026, the most recent NHSBSA release. Prescribing data publishes roughly six to eight weeks in arrears, and DoseTrend refreshes within 48 hours of each monthly release.
The full breakdown.
Every ICB, every prescribing organisation, every strength, the hospital view, and the monthly briefing PDF. Sample rows shown below with the numbers obscured.
Related pages.
See the full molecule directory, or read about the data and pricing.
Track mometasone furoate like this, every month.
£1,500 a month per molecule. Apply and we'll pre-fill Mometasone furoate for you.